At the University of Pennsylvania, genome researchers have created a method for analyzing concordant genomic aberrations for determining important regions for tumor progression, according to a paper in PLoS Genetics. Using a method called Multiple Sample Analysis, they used microarrays to create profiles of conserved aberrations in certain cancer types, allowing them to validate targets for cancer therapies.